{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-029837","form_type":"8-K","ticker":"ANEB","cik":"0001815974","company_name":"Anebulo Pharmaceuticals, Inc.","filed_at":"2022-10-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.276908+00:00","generated_at":"2026-06-22T22:50:44.469575+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Anebulo shareholders elect three Class II directors, ratify auditor at 2022 annual meeting","bullets":["Directors elected: Nat Calloway (15,985,642 for, 7,456 withheld), Areta Kupchyk (15,982,304 for, 10,794 withheld), Kenneth Lin (15,982,304 for, 10,794 withheld).","Ratification of EisnerAmper LLP as independent auditor for FY2023 approved: 15,992,762 for, 335 against, 1 abstention.","No broker non-votes on director elections; broker discretionary voting allowed on auditor ratification."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-029837","json":"https://secwatch.observer/filing/0001493152-22-029837.json","markdown":"https://secwatch.observer/filing/0001493152-22-029837.md","text":"https://secwatch.observer/filing/0001493152-22-029837.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815974/000149315222029837/0001493152-22-029837-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815974/000149315222029837/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T22:50:44.469575+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4009e0e4c16113db26417601f3a6a5d7e13394c1","claim":"Anebulo Pharmaceuticals, Inc. shareholders approved Ratification of the selection by the Audit Committee of the Board of Directors of EisnerAmper LLP as the independent registered public accounting firm of the Company for its fiscal year ending June 30, 2023. at the 2022-10-28 meeting.","evidence_excerpt":"The voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 15,992,762 335 1 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1815974/000149315222029837/0001493152-22-029837-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-10-28"}],"fact_type":"shareholder_vote"},{"claim_id":"c4672fb01b8f77fe9616b21d4f4e951a539f8b0d","claim":"Anebulo Pharmaceuticals, Inc. shareholders approved Election of Directors at the 2022-10-28 meeting.","evidence_excerpt":"Name Votes For Withheld Broker Non-Votes Nat Calloway 15,985,642 7,456 0 Areta Kupchyk 15,982,304 10,794 0 Kenneth Lin 15,982,304 10,794 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1815974/000149315222029837/0001493152-22-029837-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-10-28"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}